Maxim Group Downgrades Agile Therapeutics to Hold

Maxim Group analyst Caroline Palomeque downgrades Agile Therapeutics (NASDAQ:AGRX) from Buy to Hold.

Maxim Group analyst Caroline Palomeque downgrades Agile Therapeutics (NASDAQ:AGRX) from Buy to Hold.

Total
0
Shares
Related Posts